ReviewAnti-cancer drugs2014
Taxanes: their impact on gynecologic malignancy.
Review in Anti-cancer drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Obstetric and neonatal outcomes following taxane use during pregnancy: a systematic review.BMC cancer · 2024Pooled it
- Outcome of Combined Neoadjuvant Chemotherapy and Vitamin A in Advanced Cervical Carcinoma: A Randomized Double-Blind Clinical Trial.Asian Pacific journal of cancer prevention : APJCP · 2019Trial
- Phosphoproteomic Profiling Identifies PAK4 S474 Phosphorylation Affects Docetaxel Chemosensitivity via Modulation of Microtubule Stabilization in Breast Cancer.Biomedicines · 2026Article
- Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.Nutrition & metabolism · 2026Review
- Neoadjuvant Paclitaxel-Carboplatin Followed by Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer.International journal of women's health · 2026Article
- Computational development of mushroom-6-glucan/paclitaxel as a synergistic complementary medicine for breast cancer therapy.BMC complementary medicine and therapies · 2025Article
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- Article
- Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.MedComm · 2021Review
- Developing a Yeast Platform Strain for an Enhanced Taxadiene Biosynthesis by CRISPR/Cas9.Metabolites · 2021Article
- In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents.Nutrients · 2019Review
- Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.Cancer biology & therapy · 2019Article
- Article
- Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report.Molecular and clinical oncology · 2018Article
- Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The use of taxanes in the treatment of gynecologic malignancies has expanded tremendously over the past 30 years. Both paclitaxel and docetaxel have unique microtubule stabilizing, antiangiogenic and radiation sensitizing properties that endow them with remarkable activity as chemotherapeutic agents. As research into the appropriate dose, timing, treatment interval, and response rates have been studied, they have emerged as one of the most active agents available in the treatment of gynecologic cancer. The body of research on taxanes continues to expand especially with regard to the use of taxanes in alternative formulations and in combination with newer treatments or routes of treatment. This review focuses on the development of taxanes as an effective therapy in the treatment of gynecologic cancers and data currently available in the literature regarding their efficacy. Future directions of taxane-based chemotherapy with regards to ovarian, uterine, and cervical cancers are also addressed. There is little doubt that taxane-based chemotherapy will remain an integral part of the treatment of gynecologic cancer for the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.